My areas of expertise include: corporate governance; private equity financing; IPO of Chinese enterprises both domestically and overseas; restructuring, mergers and acquisitions, and equity incentive plans.
Prior to joining Fieldfisher, I worked at JunHe LLP for six years, during which I participated in and led numerous capital market, mergers and acquisitions, and private equity financing transactions. Recently representative IPO projects that I have completed include the listing of QuantumPharm Inc. in HKEX (02228), New Horizon in HKEX, listing of Dingdong in NYSE and listing of Domino's Pizza in HKEX. I possess extensive experience in private equity investment and corporate mergers and acquisitions, providing legal services for multinational companies in their investment, mergers and acquisitions, and business activities in China. I have assisted clients in designing transaction structure, drafting of transaction documents and negotiating major industry mergers and acquisitions and joint venture projects. I have also provided comprehensive legal services to investment institutions for their private equity/venture capital projects.
My practice mainly involves the following sectors: healthcare (including biomedical, clinical and massive health), internet/e-commerce and other value-added telecommunications, education, logistics, retail, commercial real estate, manufacturing and processing industries, farming, and food industry, etc.
During my period of working at JunHe, I was a member of the ESG research group, dedicated to researching and expanding the legal compliance of environmental, social, and governance (ESG) and ESG information disclosure for listed companies. I am capable of assisting fund/investors and enterprises in conducting ESG due diligence and ESG information disclosure.
Before joining JunHe LLP in 2017, I had successively served at another PRC prestigious law firm and an affiliate law firm of the “Big-Four” accounting firms.